Champions Oncology (CSBR) Net Income towards Common Stockholders (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Net Income towards Common Stockholders of -$279000.0 in Q1 2026, down 217.72% quarter-over-quarter from $237000.0 in Q4 2025, and down 106.21% on a YoY basis from $4.5 million in Q1 2025.
Champions Oncology (CSBR) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Champions Oncology's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$279000.0 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 106.21% year-over-year to -$279000.0; the TTM figure through Jan 2026 stood at -$2.3 million (down 136.46% YoY), while the FY2025 annual figure was $4.7 million, up 164.61% from the prior year.
- Net Income towards Common Stockholders was -$279000.0 for Q1 2026 at Champions Oncology, down from $237000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $4.5 million in Q1 2025 to a low of -$2.6 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$469117.6 across 5 years, with a median of -$319000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders tumbled 12843.75% in 2023, then jumped 277.67% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$16000.0 in 2022, then sank by 12843.75% to -$2.1 million in 2023, then soared by 135.15% to $728000.0 in 2024, then tumbled by 67.45% to $237000.0 in 2025, then sank by 217.72% to -$279000.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$279000.0 (Q1 2026), $237000.0 (Q4 2025), and -$466000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -279,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -279,000.00 |
| Oct 31, 2025 | 237,000.00 |
| Jul 31, 2025 | -466,000.00 |
| Apr 30, 2025 | -1.84 Mn |
| Jan 31, 2025 | 4.50 Mn |
| Oct 31, 2024 | 728,000.00 |
| Jul 31, 2024 | 1.31 Mn |
| Apr 30, 2024 | -109,000.00 |
| Jan 31, 2024 | -2.53 Mn |
| Oct 31, 2023 | -2.07 Mn |
| Jul 31, 2023 | -2.57 Mn |
| Apr 30, 2023 | -2.56 Mn |
| Jan 31, 2023 | -2.44 Mn |
| Oct 31, 2022 | -16,000.00 |
| Jul 31, 2022 | -319,000.00 |
| Apr 30, 2022 | -344,000.00 |
| Jan 31, 2022 | 787,000.00 |
| Oct 31, 2021 | 277,000.00 |
| Jul 31, 2021 | -172,000.00 |
| Apr 30, 2021 | -673,000.00 |